Real World Effectiveness study of mepolizumab in Severe Eosinophilic AsthmaREDES

Trial description: Severe asthma is a heterogeneous disease with an unclear prevalence, however mepolizumab had shown a benefit in the reduction of exacerbations and oral corticosteroids (OCS), but since it's been approved, it's also shown the benefit of add-on mepolizumab in Quality of Life, asthma control, Lung function. Depending on the region, or even the hospital, participants need to meet a variable threshold of blood eosinophil counts and a different number of exacerbations, to be eligible for treatment with mepolizumab. Taking advantage of the availability of these measurements in all sites, subgroup analyses of exacerbations reduction by eosinophil counts could help us further understand the different burden of disease, at different levels of asthma severity. For this study, participant's data will be collected from the source documents like medical records containing demographic data, medical, treatment and diagnostic documentation and laboratory assessments, and from the medical charts. Severe asthma participants who are currently on a biologic therapy are closely managed by their specialists. During a data collection period of 3 months, investigators will select consecutively, all their eligible participants who meet the inclusion criteria. The observational period includes 12 months pre- and 12 months post-mepolizumab initiation. The 3-months data collection period will be after the post-treatment period.